AJANTPHARM - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.0
| Stock Code | AJANTPHARM | Market Cap | 35,266 Cr. | Current Price | 2,823 ₹ | High / Low | 3,228 ₹ |
| Stock P/E | 37.4 | Book Value | 330 ₹ | Dividend Yield | 0.99 % | ROCE | 33.0 % |
| ROE | 25.7 % | Face Value | 2.00 ₹ | DMA 50 | 2,833 ₹ | DMA 200 | 2,739 ₹ |
| Chg in FII Hold | 0.29 % | Chg in DII Hold | -0.22 % | PAT Qtr | 245 Cr. | PAT Prev Qtr | 250 Cr. |
| RSI | 50.2 | MACD | -21.4 | Volume | 63,927 | Avg Vol 1Wk | 56,484 |
| Low price | 2,330 ₹ | High price | 3,228 ₹ | PEG Ratio | 4.71 | Debt to equity | 0.01 |
| 52w Index | 54.9 % | Qtr Profit Var | -2.94 % | EPS | 75.5 ₹ | Industry PE | 30.1 |
📈 Chart Patterns & Moving Averages
AJANTPHARM is trading at ₹2,823, slightly below its 50 DMA (₹2,833) but above the 200 DMA (₹2,739). This indicates short-term weakness but medium-term support. Key support lies near ₹2,750–2,770, while resistance is seen at ₹2,850–2,900.
📊 RSI & MACD
RSI at 50.2 reflects neutral momentum. MACD at -21.4 is negative, signaling short-term bearish crossover and weakness in momentum.
📉 Bollinger Bands
Price is near the mid-band, showing consolidation. A breakout above ₹2,850 could trigger recovery, while a dip below ₹2,750 may invite selling pressure.
🔎 Volume Trends
Current volume (63,927) is slightly above the 1-week average (56,484), indicating stable participation. No strong breakout signals yet.
⚡ Momentum Signals
Short-term momentum is mildly bearish due to negative MACD. Entry zone: ₹2,750–2,770. Exit zone: ₹2,900–3,000 if resistance breaks, with stop-loss below ₹2,730.
📌 Trend Status
The stock is consolidating with mild bearish bias, awaiting a breakout above resistance levels.
✅ Positive
- Strong ROCE (33.0%) and ROE (25.7%) highlight excellent capital efficiency.
- Debt-to-equity ratio at 0.01 indicates virtually debt-free balance sheet.
- EPS at ₹75.5 supports earnings visibility.
- FII holdings increased (+0.29%), showing foreign investor confidence.
⚠️ Limitation
- P/E ratio (37.4) higher than industry average (30.1), suggesting overvaluation.
- PEG ratio at 4.71 indicates expensive valuation relative to growth.
- DII holdings decreased (-0.22%), showing cautious domestic sentiment.
- Quarterly profit variation (-2.94%) reflects minor decline in earnings momentum.
❌ Company Negative News
- Minor decline in quarterly PAT (₹245 Cr vs ₹250 Cr).
- MACD (-21.4) indicates short-term bearish trend.
🌟 Company Positive News
- Strong fundamentals with high ROE and ROCE.
- Dividend yield of 0.99% provides modest income support.
- Stable trading volumes indicate consistent investor interest.
🏭 Industry
- Industry P/E at 30.1, slightly lower than company’s valuation.
- Pharma sector supported by long-term demand and innovation-driven growth.
📌 Conclusion
AJANTPHARM is fundamentally strong but currently consolidating with mild bearish signals. Entry near ₹2,750–2,770 offers margin of safety, while profit booking is advised near ₹2,900–3,000 unless breakout occurs above ₹3,050 with strong volume. Suitable for long-term investors with disciplined stop-loss management.
This version is tuned for short-term trading signals with fundamental overlays. Would you like me to also prepare a multi-horizon view (intraday, swing, and investment) for AJANTPHARM so you can benchmark across timeframes?